Opinion
Video
Management of Resectable Early Stage NSCLC with Actionable Mutations
Author(s):
The panel discusses management of resectable early-stage non–small cell lung cancer.
EP: 1.Patient with Stage IIIB NSCLC with No Actionable Mutations and PD-L1 TPS 0%
EP: 2.Biomarker Testing and the Multidisciplinary Approach in Early-Stage NSCLC
EP: 3.Navigating Neoadjuvant and Perioperative Treatment Strategies in Early Stage NSCLC
EP: 4.Treatment Considerations for Neoadjuvant and Perioperative Therapy in ES NSCLC
EP: 5.Management of Borderline Resectable NSCLC
Now Viewing
EP: 6.Management of Resectable Early Stage NSCLC with Actionable Mutations
EP: 7.Considerations for Combination of Adjuvant Chemotherapy and Targeted Therapy in Resectable ES NSCLC
EP: 8.Patient with Unresectable Stage IIIB EGFR-Mutant NSCLC with N2 Bulky Disease
EP: 9.Expert Perspectives on Patient Selection for cCRT and sCRT in Unresectable ES NSCLC
EP: 10.Treatment Considerations for Consolidation Durvalumab in Unresectable ES NSCLC
Video content above is prompted by the following:
How does your approach differ based on PD-L1 status? Presence of EGFR/ALK alterations?
Related Videos
Related Content
